Compare DexCom, Inc. (DXCM) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zscaler Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Zscaler Inc trades at $233.73 (market cap $35.35B). The key difference: DexCom, Inc. and Zscaler Inc are close in size by market cap, and DexCom, Inc. is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Zscaler Inc for 41 Days on average.
| DXCM | ZS | |
|---|---|---|
Market Cap | $31.86B | $35.35B |
Volume | 3,607,070 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $92.34 | $336.27 |
52-Week Low | $54.84 | $118.05 |
Typical Hold Time | 62 Days | 41 Days |
Enterprise Value | $31.32B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Zscaler (ZS) trades at $216.99, up 1.61% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent quarters have consistently beaten EPS estimates, while analyst sentiment remains overwhelmingly positive with 79.63% buy ratings and a $222.83 consensus target.
ZS presents growth potential through cybersecurity demand and AI product expansion, but faces execution risks from leadership changes and competitive pressures. The stock trades at premium valuations (P/S 10.36) while still losing money, creating both opportunity and vulnerability if growth slows or margins don't improve as expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
